6533b824fe1ef96bd1280a46

RESEARCH PRODUCT

Hyperalgesia and opioid switching

Sebastiano MercadanteEdoardo Arcuri

subject

MaleTime FactorsPainContext (language use)Drug Administration ScheduleFentanyl03 medical and health sciences0302 clinical medicine030502 gerontologymedicineHumansAdverse effectPain Measurementbusiness.industryPatient SelectionPalliative CareSarcomaDrug ToleranceGeneral MedicineMiddle AgedThoracic NeoplasmsAnalgesics OpioidFentanylTherapeutic EquivalencyOpioidHyperalgesia030220 oncology & carcinogenesisAnesthesiaHyperalgesiaDrug Monitoringmedicine.symptom0305 other medical scienceCancer painbusinessMethadonemedicine.drugMethadone

description

Opioids, intended to abolish pain, can unexpectedly produce hyperalgesia, particularly during rapid opioid escalation. Opioid switching could be a therapeutic option in a condition of opioid-induced tolerance or hyperalgesia, but conversion ratios between opioids are difficult to apply in this context and require strict surveillance and expertise. This situation is challenging, because the rapid escalation of opioid doses, possibly due to the development of opioid-induced tolerance, can cause hyperalgesia. To avoid this adverse effect, clinicians need to refine their assessment of pain treatment and consider opioid switching. The authors present a case report in which switching from fentanyl to methadone was effective in a patient who developed hyperalgesia as a consequence of a rapid opioid escalation. Regardless of the expected clinical improvement of opioid switching using lower doses of the second opioid, the final dose of the second opioid was exaggeratedly low, probably as a consequence of the disappearance of hyperalgesia induced by the first opioid. The results of this case and others like it may help practitioners develop a meaningful approach during opioid escalation, possibly anticipating the need for opioid switching or other alternative measures for patients with uncontrolled cancer pain.

https://doi.org/10.1177/104990910502200411